| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cd7ebabb297f0d8cb3f2c0b100dfe7ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2786720cd363efcd84f5fd6492510e49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d00ed3f58012d67abe5e9ed518adf90c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_429470af250b752572727b5a2a89e211 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 |
| filingDate |
2011-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc1fb603451175230a59919c95e2c62a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a73029a23f5b9960f82e9c22971dce97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cef803e4b615ac8eb6eec3d3322256bd |
| publicationDate |
2015-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9205086-B2 |
| titleOfInvention |
Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
| abstract |
A pharmaceutical combination comprising an EGFR inhibitor and an Hsp90 inhibitor according to the following formulae (I) or (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof using pharmaceutical combinations disclosed herein. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9539243-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9402831-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10500193-B2 |
| priorityDate |
2010-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |